Tymcure Ltd., established in 2014, is a leading brand in the medical field, specializing in tympanic membrane perforation treatment. As part of CTZ Medical's portfolio, Tymcure offers a novel solution to address the unmet need for surgeons in this area. The brand's revolutionary technology, licensed from Mor research applications, the largest HMO in Israel and second worldwide, has been developed by a dynamic management team supported by a strong scientific team.

The team includes professionals with extensive experience in biotechnology, medical devices, and otorhinolaryngology-head and neck surgery. Led by CEO Eyal Aviram and clinical director Ariel Margulis MD, Tymcure boasts a proficient director of R&D, Mazal Dahan, PhD, and director of device R&D, Eng. Nir Lilach.

With highly skilled individuals like Vered Alon, QA Manager, Amir Shachar, Production Engineer, and CFO Oded Isvoranu, Tymcure ensures the highest quality in their products. Backed by CTZ's board of directorate, which includes CEO Erez Zelnik and Chairman Roni Talic, Tymcure is committed to revolutionizing healthcare with their innovative solutions. For more information, please visit their website or contact them directly